Published in Neuroimaging Clin N Am on November 01, 2005
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Automatic classification of MR scans in Alzheimer's disease. Brain (2008) 6.71
The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex (2008) 5.36
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage (2006) 3.85
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Cluster failure: Why fMRI inferences for spatial extent have inflated false-positive rates. Proc Natl Acad Sci U S A (2016) 3.72
Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage (2008) 3.40
Multi-parametric neuroimaging reproducibility: a 3-T resource study. Neuroimage (2010) 3.32
Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res (2009) 3.31
Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage (2010) 3.27
Data sharing in neuroimaging research. Front Neuroinform (2012) 2.92
Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology (2009) 2.90
Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimers Dement (2010) 2.79
Voxelwise genome-wide association study (vGWAS). Neuroimage (2010) 2.69
3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. Neuroimage (2008) 2.40
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls. Neuroimage (2008) 2.30
Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects. Neuroimage (2009) 2.28
Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Hum Brain Mapp (2009) 2.28
Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage (2008) 2.25
Structural MRI biomarkers for preclinical and mild Alzheimer's disease. Hum Brain Mapp (2009) 2.24
Detection of cortical thickness correlates of cognitive performance: Reliability across MRI scan sessions, scanners, and field strengths. Neuroimage (2007) 2.23
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol (2015) 2.21
A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly. Proc Natl Acad Sci U S A (2010) 2.12
LEAP: learning embeddings for atlas propagation. Neuroimage (2009) 2.09
The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement (2010) 2.09
Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol Aging (2010) 2.05
Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage (2009) 2.03
Is it time to re-prioritize neuroimaging databases and digital repositories? Neuroimage (2009) 1.83
Interpreting scan data acquired from multiple scanners: a study with Alzheimer's disease. Neuroimage (2007) 1.83
Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. PLoS One (2011) 1.79
Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials. Neuroimage (2012) 1.76
Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. Neuroimage (2009) 1.71
Obesity is linked with lower brain volume in 700 AD and MCI patients. Neurobiol Aging (2010) 1.69
Mapping Alzheimer's disease progression in 1309 MRI scans: power estimates for different inter-scan intervals. Neuroimage (2010) 1.69
Multi-source feature learning for joint analysis of incomplete multiple heterogeneous neuroimaging data. Neuroimage (2012) 1.66
Diagnostic neuroimaging across diseases. Neuroimage (2011) 1.66
Accuracy of dementia diagnosis: a direct comparison between radiologists and a computerized method. Brain (2008) 1.64
Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls. Neuroimage (2009) 1.63
Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry. Hum Brain Mapp (2010) 1.55
Executive function and instrumental activities of daily living in mild cognitive impairment and Alzheimer's disease. Alzheimers Dement (2011) 1.54
Functional impairment in elderly patients with mild cognitive impairment and mild Alzheimer disease. Arch Gen Psychiatry (2011) 1.50
Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol (2009) 1.47
Surface-based TBM boosts power to detect disease effects on the brain: an N=804 ADNI study. Neuroimage (2011) 1.41
Brain MAPS: an automated, accurate and robust brain extraction technique using a template library. Neuroimage (2010) 1.37
Comparison of manual and automated determination of hippocampal volumes in MCI and early AD. Brain Imaging Behav (2010) 1.36
Decisional capacity for research participation in individuals with mild cognitive impairment. J Am Geriatr Soc (2008) 1.35
Magnetic Resonance Image Example-Based Contrast Synthesis. IEEE Trans Med Imaging (2013) 1.35
Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease. Alzheimer Dis Assoc Disord (2010) 1.33
Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study. BMC Neurol (2010) 1.32
Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. Neurobiol Aging (2010) 1.30
Pooling FMRI data: meta-analysis, mega-analysis and multi-center studies. Front Neuroinform (2009) 1.28
Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity. Proc Natl Acad Sci U S A (2013) 1.26
Inverse-consistent surface mapping with Laplace-Beltrami eigen-features. Inf Process Med Imaging (2009) 1.25
Impact of scanner hardware and imaging protocol on image quality and compartment volume precision in the ADNI cohort. Neuroimage (2009) 1.25
Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol (2015) 1.23
Automatic detection of preclinical neurodegeneration: presymptomatic Huntington disease. Neurology (2009) 1.22
Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. Neurobiol Aging (2010) 1.22
Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease. Radiology (2010) 1.22
Mapping anterior temporal lobe language areas with fMRI: a multicenter normative study. Neuroimage (2010) 1.21
Magnetic resonance imaging characterization of brain structure and function in mild cognitive impairment: a review. J Am Geriatr Soc (2008) 1.20
Nonlinear time course of brain volume loss in cognitively normal and impaired elders. Neurobiol Aging (2010) 1.19
Loss of cerebral white matter structural integrity tracks the gray matter metabolic decline in normal aging. Neuroimage (2008) 1.18
Knowledge-guided robust MRI brain extraction for diverse large-scale neuroimaging studies on humans and non-human primates. PLoS One (2014) 1.18
Prediction of Alzheimer's disease in subjects with mild cognitive impairment from the ADNI cohort using patterns of cortical thinning. Neuroimage (2012) 1.17
Multi-site voxel-based morphometry: methods and a feasibility demonstration with childhood absence epilepsy. Neuroimage (2008) 1.17
The MCIC collection: a shared repository of multi-modal, multi-site brain image data from a clinical investigation of schizophrenia. Neuroinformatics (2013) 1.14
Depressive symptoms in mild cognitive impairment predict greater atrophy in Alzheimer's disease-related regions. Biol Psychiatry (2012) 1.13
Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark Med (2010) 1.12
Comparison of imaging biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging. Arch Neurol (2012) 1.11
Robust surface reconstruction via Laplace-Beltrami eigen-projection and boundary deformation. IEEE Trans Med Imaging (2010) 1.10
Sparse bayesian learning for identifying imaging biomarkers in AD prediction. Med Image Comput Comput Assist Interv (2010) 1.10
Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline. Neurobiol Aging (2010) 1.09
Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease. J Alzheimers Dis (2010) 1.07
Neuropsychiatric symptoms and global functional impairment along the Alzheimer's continuum. Dement Geriatr Cogn Disord (2012) 1.07
Update on amyloid imaging: from healthy aging to Alzheimer's disease. Curr Neurol Neurosci Rep (2009) 1.07
Cortical surface reconstruction via unified Reeb analysis of geometric and topological outliers in magnetic resonance images. IEEE Trans Med Imaging (2013) 1.04
Maximizing power to track Alzheimer's disease and MCI progression by LDA-based weighting of longitudinal ventricular surface features. Neuroimage (2013) 1.03
Bi-level multi-source learning for heterogeneous block-wise missing data. Neuroimage (2013) 1.02
Effects of hardware heterogeneity on the performance of SVM Alzheimer's disease classifier. Neuroimage (2011) 1.02
Instrumental activities of daily living impairment is associated with increased amyloid burden. Dement Geriatr Cogn Disord (2011) 1.01
Fast and accurate modelling of longitudinal and repeated measures neuroimaging data. Neuroimage (2014) 1.00
Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA Study. Neuroepidemiology (2008) 1.00
Reliability of neuroanatomical measurements in a multisite longitudinal study of youth at risk for psychosis. Hum Brain Mapp (2013) 0.99
Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement (2015) 0.98
Greater regional brain atrophy rate in healthy elderly subjects with a history of cigarette smoking. Alzheimers Dement (2012) 0.98
Functional connectivity measured with magnetoencephalography identifies persons with HIV disease. Brain Imaging Behav (2012) 0.96
Dissecting the gene dose-effects of the APOE ε4 and ε2 alleles on hippocampal volumes in aging and Alzheimer's disease. PLoS One (2013) 0.96
High dimensional classification of structural MRI Alzheimer's disease data based on large scale regularization. Front Neuroinform (2011) 0.96
Relationship between baseline brain metabolism measured using [¹⁸F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease. Brain Imaging Behav (2012) 0.96
Genetic influence of apolipoprotein E4 genotype on hippocampal morphometry: An N = 725 surface-based Alzheimer's disease neuroimaging initiative study. Hum Brain Mapp (2014) 0.96
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol (2012) 0.94
Structural neuroimaging in the detection and prognosis of pre-clinical and early AD. Behav Neurol (2009) 0.93
Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron (2014) 0.93
Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer's disease. Brain Imaging Behav (2012) 0.92
Mild cognitive impairment as a diagnostic entity. J Intern Med (2004) 26.95
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
Toxic proteins in neurodegenerative disease. Science (2002) 5.82
Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci (2003) 4.75
Comparison of automated and manual MRI volumetry of hippocampus in normal aging and dementia. J Magn Reson Imaging (2002) 3.34
Treatment of Alzheimer's disease. N Engl J Med (1999) 3.03
Looking backward to move forward: early detection of neurodegenerative disorders. Science (2003) 2.65
Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol (2002) 2.58
Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Med (2003) 2.49
Biomarkers of Alzheimer disease in plasma. NeuroRx (2004) 2.02
Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci (2002) 1.83
CSF biomarkers for mild cognitive impairment. J Intern Med (2004) 1.56
The current status of Alzheimer's disease genetics: what do we tell the patients? Pharmacol Res (2004) 1.53
The CERAD experience, Part VIII: Neuroimaging-neuropathology correlates of temporal lobe changes in Alzheimer's disease. Neurology (1995) 1.51
Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta Neuropathol (1996) 1.49
Alzheimer disease therapeutics. J Neuropathol Exp Neurol (2001) 1.25
Pathology and pathways of Alzheimer's disease with an update on new developments in treatment. J Am Geriatr Soc (2003) 1.22
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron (2011) 20.15
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci U S A (2004) 17.86
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med (2005) 12.04
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Mild cognitive impairment. Lancet (2006) 10.21
Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke (2011) 10.11
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Mapping cortical change across the human life span. Nat Neurosci (2003) 8.98
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci (2007) 7.96
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90
Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron (2010) 7.87
High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA (2008) 7.35
Longitudinal mapping of cortical thickness and brain growth in normal children. J Neurosci (2004) 7.30
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol (2004) 7.07
Construction of a 3D probabilistic atlas of human cortical structures. Neuroimage (2007) 7.04
Dynamics of gray matter loss in Alzheimer's disease. J Neurosci (2003) 7.03
Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (2012) 6.66
Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template. Neuroimage (2008) 6.58
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol (2007) 6.58
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA (2003) 6.34
Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science (2001) 6.15
Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron (2007) 6.07
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology (2008) 5.94
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
The LONI Pipeline Processing Environment. Neuroimage (2003) 5.47
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature (2010) 5.26
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol (2012) 5.18
Frontotemporal dementia: clinicopathological correlations. Ann Neurol (2006) 5.14
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage (2004) 5.07
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol (2007) 5.02
Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement (2010) 4.85
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron (2002) 4.77
Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron (2011) 4.74
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol (2004) 4.66
Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol (2006) 4.56
Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage (2007) 4.41
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol (2012) 4.36
Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol (2006) 4.32
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol (2011) 4.15
Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci (2004) 4.14
Mapping cortical change in Alzheimer's disease, brain development, and schizophrenia. Neuroimage (2004) 4.13
Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain (2006) 4.07
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov (2007) 4.03
Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature (2013) 4.03
Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet (2009) 4.00
Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med (2012) 3.98
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging (2009) 3.97
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med (2004) 3.93
Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain (2013) 3.87
Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage (2006) 3.85
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol (2002) 3.84
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Initiation and synergistic fibrillization of tau and alpha-synuclein. Science (2003) 3.76